Budget Impact of Strategies Involving RSVpreF and Nirsevimab to Protect Infants in Saudi Arabia Against Respiratory Syncytial Virus.

Alharbi AS, Abu-Shraie N, Al Abdulkarim H, Alharbi IH, Averin A, Law AW, Mendes D, Quinn E, Zayed M, Behiry A, Haridy H, Mousa M

Open source

DOI: 10.1007/s40121-026-01386-5
Published: 2026 Jun 17
Container: Infectious diseases and therapy
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40121-026-01386-5,
  title = {Budget Impact of Strategies Involving RSVpreF and Nirsevimab to Protect Infants in Saudi Arabia Against Respiratory Syncytial Virus.},
  author = {Alharbi AS and Abu-Shraie N and Al Abdulkarim H and Alharbi IH and Averin A and Law AW and Mendes D and Quinn E and Zayed M and Behiry A and Haridy H and Mousa M},
  year = {2026},
  journal = {Infectious diseases and therapy},
  doi = {10.1007/s40121-026-01386-5},
  url = {https://doi.org/10.1007/s40121-026-01386-5}
}

RIS

TY  - JOUR
TI  - Budget Impact of Strategies Involving RSVpreF and Nirsevimab to Protect Infants in Saudi Arabia Against Respiratory Syncytial Virus.
AU  - Alharbi AS
AU  - Abu-Shraie N
AU  - Al Abdulkarim H
AU  - Alharbi IH
AU  - Averin A
AU  - Law AW
AU  - Mendes D
AU  - Quinn E
AU  - Zayed M
AU  - Behiry A
AU  - Haridy H
AU  - Mousa M
PY  - 2026
JO  - Infectious diseases and therapy
DO  - 10.1007/s40121-026-01386-5
UR  - https://doi.org/10.1007/s40121-026-01386-5
ER  -

APA

AS, A., N, A., H, A. A., IH, A., A, A., AW, L., D, M., E, Q., M, Z., A, B., H, H., & M, M. (2026). Budget Impact of Strategies Involving RSVpreF and Nirsevimab to Protect Infants in Saudi Arabia Against Respiratory Syncytial Virus.. Infectious diseases and therapy. https://doi.org/10.1007/s40121-026-01386-5

Source records

pubmed · retrieved 2026-09-25T21:39:28.828Z